Risk Factors Update Summary

• The company may incur losses in the future due to changes in government policies, including potential losses from Medicare reimbursement changes in calendar year 2025 or thereafter.
• CMS exempted skin substitutes from refund requirements in 2023, but uncertainty remains about potential refunds for discarded product portions.
• The company may incur losses in the future despite reported net income, with an accumulated deficit of $41.0 million as of December 31, 2023.
• The company faces risks related to cybersecurity threats, potential breaches, and the need for significant resources to maintain IT infrastructure.
• Identified weaknesses in internal controls over financial reporting, with ongoing efforts to remediate material weaknesses.
• Risks related to the acquisition of NuTech Medical and CPN Biosciences, including challenges in selling required products and diverting management's attention.
• Changes in patent laws and regulations could impact the company's ability to protect its products, with potential adverse effects on business operations.